The use of D-mannose in the prevention of recurrent urinary tract infections

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Urinary tract infections (UTIs) are a common problem, especially among women. An imbalance of urogenital bacteria caused by frequent sexual intercourse or postmenopausal age is a risk factor for UTIs. Frequent infections and the use of antibiotics lead to changes in the urogenital microbiota. In particular, the use of antibiotics may influence the prevalence of indigenous lactobacilli and potentially create a suitable environment for the proliferation of uropathogens. At the same time, antibiotic resistance is becoming an increasingly serious problem in medicine, especially in the prevention and treatment of recurrent UTIs. In this regard, the search for new alternative approaches becomes a necessity. One such potential solution is the use of D-mannose. D-mannose is a monosaccharide, a natural aldohexose sugar, distinguished from glucose by the inversion of one of the 4 chiral centers of the molecule: the carbon atom in the second position. This sugar is physiologically present in the human body, participates in immunoregulation and plays other important biological roles such as glycosylation of many proteins. Another property of D-mannose has been discovered: it inhibits bacterial adhesion to the urothelium. It is a key component of glycoproteins that play an important role in normal urinary tract function. A systematic analysis of 33,064 studies by I.Yu. Torshin et al. in 2020 showed other significant effects of D-mannose: its importance for protein glycosylation, supporting the immune, cardiovascular, urinary and other body systems. Disorders of D-mannose metabolism are integral component of the pathogenesis of autoimmune diseases (type 1 diabetes mellitus, Crohn’s disease, rheumatoid arthritis, etc.). In addition, disturbances in the levels and activity of D-mannose-dependent proteins are associated with an increased risk of bacterial cystitis and tumor pathologies. The analyzed literature also demonstrated that the bacteriostatic, anti-inflammatory and antitumor effects of D-mannose are enhanced by the prebiotic (metabiotic) inulin. In combination with inulin, D-mannose inhibits the growth of pathogenic bacteria and simultaneously supports the growth of beneficial intestinal microbiota. We reviewed the literature to evaluate the effect of D-mannose in the prevention of recurrent UTIs.

全文:

受限制的访问

作者简介

Tatyana Teterina

National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov

编辑信件的主要联系方式.
Email: palpebra@inbox.ru
ORCID iD: 0000-0003-0990-2302

Cand. Sci. (Med.), Obstetrician-Gynecologist, Ultrasound Doctor at the Department of Aesthetic Gynecology and Rehabilitation, National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov; Expert of the Association of Specialists in Aesthetic Gynecology (ASAG)

俄罗斯联邦, Moscow

L. Tarnaeva

National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov

Email: palpebra@inbox.ru
ORCID iD: 0009-0006-7500-7516
俄罗斯联邦, Moscow

I. Apolikhina

National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: palpebra@inbox.ru
ORCID iD: 0000-0002-4581-6295
俄罗斯联邦, Moscow; Moscow

参考

  1. EAU guidelines, 2024. URL: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2024.pdf
  2. Pigrau C., Escola-Verge L. Recurrent urinary tract infections: from pathogenesis to prevention. Med. Clin. (Barc). 2020;155(4):171–77. English, Spanish. doi: 10.1016/j.medcli.2020.04.026.
  3. Кузьмин И.В., Слесаревская М.Н., Аль-Шукри С.Х. Неантибактериальная профилактика посткоитального цистита у женщин. Русский медицинский журнал. Мать и дитя. 2021;4(3):209–17. [Kuzmin I.V., Slesarevskaya M.N., Al-Shukri S.Kh. Non-antibacterial prophylaxis of postcoital cystitis in women. Russkii meditsinskii zhurnal. Mat’ i ditya=Russian Medical Journal. Mother and Child. 2021;4(3):209–17. (In Russ.)]. doi: 10.32364/2618-8430-2021-4-3-209-217.
  4. Aronson M., Medalia O., Schori L., et al. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside. J Infect Dis. 1979;139(3):329–32. doi: 10.1093/infdis/139.3.329.
  5. Торшин И.Ю., Аполихина И.А., Громов А.Н., Громова О.А. Свойства D-маннозы: противовоспалительный и противоопухолевый эффекты. Экспериментальная и клиническая урология. 2020;(2):164–70. [Torshin I.Yu., Apolikhina I.A., Gromov A.N., Gromova O.A. Properties of D-mannose: anti-inflammatory and antitumor effects. Eksperimental’naya i klinicheskaya urologiya. 2020;(2):164–70. (In Russ.)].
  6. Кульчавеня Е.В., Трейвиш Л.С., Телина Е.В. Альтернативные виды терапии рецидивирующего цистита у женщин в менопаузе. Медицинский совет. 2022;16(14):164–70. [Kulchavenya E.V., Treyvish L.S., Telina E.V. Alternative therapies for recurrent cystitis in postmenopausal women. Meditsinskii sovet=Medical Council. 2022;16(14):164–70. (In Russ.)]. doi: 10.21518/2079-701X-2022-16-14-164-170.
  7. Postma P.W., Lengeler J.W., Jacobson G.R. Phosphoenolpyruvate: carbohydrate phosphotransferase systems of bacteria. Microbiol Rev. 1993;57(3):543–94. doi: 10.1128/mr.57.3.543-594.1993.
  8. Громова О.А., Торшин И.Ю., Галустян А.Н. и др. Хемомикробиомный анализ синергизма D-маннозы и D-фруктозы в сравнении с молекулами других метабиотиков. Эффективная фармакотерапия. Урология и нефрология. 2020;(2). [Gromova O.A., Tor- shin I.Yu., Galustyan A. N., et al. Chemomicrobiome analysis of D-mannose and D-fructose synergism in comparison with other metabiotic molecules. Effektivnaya farmakoterapiya. Urologiya i nefrologiya=Effective pharmacotherapy. Urology and nephrology. 2020;(2). (In Russ.)].
  9. Dalziel M., Crispin M., Scanlan C.N., et al. Emerging principles for the therapeutic exploitation of glycosylation. Science. 2014;343(6166):1235681. doi: 10.1126/science.1235681.
  10. Громова О.А., Торшин И.Ю., Тетруашвили Н.К. Систематический анализ исследований по D-маннозе и перспективы ее применения при рецидивирующих инфекциях мочеполовых путей у женщин репродуктивного возраста. Акушерство, гинекология, репродукция, 2019;13(2):119–31. [Gromova O.A., Torshin I.Yu., Tetruashvili N.K. Systematic analysis of studies on D-mannose and prospects for its use in recurrent urogenital tract infections in women of reproductive age. Akusherstvo, ginekologiya, reproduktsiya=Obstetrics, Gynecology and Reproduction. 2019;13(2):119–31. (In Russ.)]. doi: 10.17749/2313-7347.2019. 13.2.119-131.
  11. Kyriakides R., Jones P., Somani B.K. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus. 2021;7(5):1166–69. doi: 10.1016/j.euf.2020.09.004.
  12. Schwartz D.J., Kalas V., Pinkner J.S., et al. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc Natl Acad Sci USA. 2013;110(39):15530–37. doi: 10.1073/pnas.1315203110.
  13. Loubet P., Ranfaing J., Dinh A., et al. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. Front Microbiol. 2020;11:1509. doi: 10.3389/fmicb.2020.01509.
  14. Porru D., Parmigiani A., Tinelli C., et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clin Urol. 2014; 7:208–13.
  15. Kranjcec B., Papes D., Altarac S. D-Mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32:79–84. doi: 10.1007/s00345-013-1091-6.
  16. Altarac S., Papes D. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int. 2014;113(1):9–10. doi: 10.1111/bju.12492.
  17. Del Popolo G., Nelli F. Recurrent bacterial symptomatic cystitis: a pilot study on a new natural option for treatment. Arch Ital Urol Androl. 2018;9:101–3. doi: 10.4081/aiua.2018.2.101.
  18. Domenici L., Monti M., Bracchi C., et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016;20(13):2920–25.
  19. Panchev P., Slavov C., Mladenov D., et al. A multicenter comparative observation on the effectiveness and the rapidness of the effect of Cystostop rapid versus antibiotic therapy in patients with uncomplicated cystitis. Akush Ginekol. (Sofiia) 2012;51(7):49–55.
  20. Scaglione F., Musazzi U.M., Minghetti P. Considerations on D-mannose mechanism of action and consequent classification of marketed healthcare products. Front Pharmacol. 2021;12:636377. doi: 10.3389/fphar.2021.636377.
  21. Khandelwal P., Abraham S.N., Apodaca G. Cell biology and physiology of the uroepithelium. Am J Physiol Ren Physiol. 2009;297(6):F1477–501. doi: 10.1152/ajprenal.00327.2009.
  22. Spaulding C.N., Klein R.D., Ruer S., et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature. 2017;546:528–32. doi: 10.1038/nature22972.
  23. Bouckaert J., Berglund J., Schembri M., et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesion. Mol Microbiol. 2005;55: 441–55. doi: 10.1111/j.1365-2958.2004. 04415.x.
  24. Ala-Jaakkola R., Laitila A., Ouwehand A.C., Lehtoranta L. Role of D-mannose in urinary tract infections – a narrative review. Nutr J. 2022;21(1):18. doi: 10.1186/s12937-022-00769-x.
  25. Murina F., Vicariotto F., Lubrano C. Efficacy of an orally administered combination of Lactobacillus paracasei LC11, cranberry and D-mannose for the prevention of uncomplicated, recurrent urinary tract infections in women. Urologia. 2021;88(1):64–8.
  26. Salinas-Casado J., Mendez-Rubio S., Esteban-Fuertes M., et al. Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections. Arch Esp Urol. 2018;71(2):169–77.
  27. Salinas-Casado J., Mendez-Rubio S., Esteban-Fuertes M., et al. Large study (283 women) on the effectiveness of Manosar(R): 2 g of d-mannose+140 mg of proanthocyanidins (PAC), of prolonged release. Arch Esp Urol. 2020;73(6):491–98.
  28. Gill C.M., Hughes M.A., LaPlante K.L. A Review of Nonantibiotic Agents to Prevent Urinary Tract Infections in Older Women. J Am Med Dir Assoc. 2020;21(1):46–54. doi: 10.1016/j.jamda.2019.04.018.
  29. Russo E., Montt Guevara M., Giannini A., et al. D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery. Climacteric. 2020;23(2):201–5. doi: 10.1080/13697137.2019.1679110.
  30. Chiu K., Zhang F., Sutcliffe S., et al. Recurrent urinary tract infection incidence rates decrease in women with cystitis cystica after treatment with D-mannose: a cohort study. Female Pelvic. Med Reconstr Surg. 2022;28(3):e62–5. doi: 10.1097/SPV.0000000000001144.
  31. Тетерина Т.А., Ищук М.П., Аполихина И.А. Современные подходы к терапии и профилактике рецидивирующих циститов у беременных с применением D-маннозы: результаты проспективного рандомизированного клинического исследования. Эффективная фармакотерапия. 2021;17(9):6–14. Teterina T.A., Ishchuk M.P., Apolikhina I.A. Modern approaches to the therapy and prevention of recurrent cystitis in pregnant women using D-mannose: results of a prospective randomized clinical trial. Effektivnaya farmakoterapiya=Effective pharmacotherapy. 2021;17(9):6–14. (In Russ.)].
  32. Li W.G., Zhang X.Y., Wu Y.J., Tian X. Anti-inflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol Sin. 200;22(12):1117–20.
  33. Chang W.C., Hsu F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostaglandins, Leukot Essent Fat Acids. 1989;38(3):181–88. doi: 10.1016/0952-3278(89)90070-7.
  34. Quintus J., Kovar K.-A., Link P., Hamacher H. Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts. Planta Med. 2005;71(2):147–52. doi: 10.1055/s-2005-837782.
  35. Geetha R.V., Roy A., Lakshmi T. Nature’s weapon against urinary tract infections. Int J Drug Dev Res. 2011;3(3):85–100.
  36. Rotblatt M. Herbal Medicine: Expanded Commission E Monographs. Ann Intern Med. 2013;133(6):ID487. doi: 10.7326/0003-4819-133-6-200009190-00031.
  37. Lenger S.M., Bradley M.S., Thomas D.A., et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265.e1–5.e13. doi: 10.1016/j.ajog.2020.05.048.
  38. Сommittee on herbal medicinal products (HMPC). Assessmen report on Arctostaphylos uva-ursi (L.) Spreng., folium. European Medicines Agency. 2012. P. 1–34.
  39. Ochoa-Brust G.J., Fernandez A.R., Villanueva-Ruiz G.J., et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007;86(7):783–87. doi: 10.1080/00016340701273189.
  40. Шорманов И.С., Соловьев А.С., Чирков И.А. и др. Возможности препаратов на основе D-маннозы и растительных компонентов в лечении и профилактике рецидивирующих инфекций нижних мочевых путей у женщин. Урологические ведомости. 2022;12(1):13–20. Shormanov I.S., Soloviev A.S., Chirkov I.A. et al. Possibilities of drugs based on D-mannose and herbal components in the treatment and prevention of recurrent lower urinary tract infections in women. Urologicheskie vedomosti. 2022;12(1):13–20. (In Russ.)]. doi: 10.17816/uroved84084.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2024
##common.cookie##